Table 5. . Nanostructured lipid carrier fabricated using ultrasonication technique.

Active ingredient	Solid lipid	Liquid lipid	Surfactants	Size (nm)	Research highlights	Ref.
Domperidone	Trimyristin	Cetyl recinoleate	Soy phosphatidyl choline, Tween 80	30.45	In vitro release studies demonstrated controlled release of drug over 24 h NLCs were stable during 40 days storage period of time	[21]
Fenofibrate	Compritol 888 ATO	Labrafil M 1944CS	Tween 80, soya lecithin	89.9 ± 4.9	Four-fold improvement in AUC	[47]
Lutein	Precirol® ATO 5	Corn oil	Pluronic F 68, Myverol 18–04 K	130	Improvement in aqueous solubility of lutein after encapsulation in NLCs Sustained release of lutein was achieved	[48]
Miconazole	Gelucine® 43/01	Miglyol® 812	Benzlalkonium chloride, Tween 80	≈200	Drug loaded in NLCs showed similar therapeutic efficacy to the marketed formulations having 17-fold higher dose of drug	[49]
Vinpocetine	Compritol 888 ATO	Migylol® 812	Solutol HS-15	89 ± 21	Relative bioavailability of solid vinpocetine-cyclodextrin tartaric acid-loaded NLCs was 592% higher in comparison to vinpocetine suspension and 92% in comparison to conventional NLCs	[50]

AUC: Area under curve; NLC: Nanostructured lipid carrier.